Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 122-128

  Takahashi, Hiroaki ^a   Arimura, Yoshiaki ^b   Yamashita, Kentaro ^b   Okahara, Satoshi ^b   Tanuma, Tokuma ^b   Kodaira, Junichi ^a   Hokari, Kaku ^a   Tsukagoshi, Hiroyuki ^a   Shinomura, Yasuhisa ^b   Hosokawa, Masao ^a  

^a Keiyukai Sapporo Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Docetaxel (TXT); Esophagus; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 76149118409     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c1ffd5     Document Type: Article

References (36)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
2. Levard H, Pouliquen X, Hay JM, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomized controlled trial. The French Associations for Surgical Research. Eur J Surg 1998;164:849-857.
3. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22: 172-176.
4. Zhang X, Shen L, Li J, Li Y, Li J, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 2008;31:29-33.
5. Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005;16:1320-1325.
6. Polee MB, Kok TC, Siersema PD, et al. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 2001;12:513-517.
7. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704.
8. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 2006;24:4991-4997.
10. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
11. Díaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-2755.
12. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-959.
13. Higuchi K, Koizumi W, Tanabe S, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol 2008;87:398-404.
14. Tanaka T, Sueyoshi S, Sasahara H, et al. Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer-a pilot study. Jpn J Cancer Chemother 2003;30:1955-1958.
15. Tanaka T, Fujita H, Sueyoshi S, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: A preliminary report of initial experience. Chemotherapy 2007;53:449-453.
16. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005;16: 1133-1139.
17. Evans D, Miner T, Iannitti D, et al. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: A phase II study. Cancer Invest 2007;25:445-448. (Pubitemid 47450681)
18. Hejna M, Raderer M, Zacherl J, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS. 1.2.001. Anticancer Drugs 2008;19: 535-539.
19. Registration Committee for Esophageal Cancer. In: Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) & Long-term Result of Esophagectomy in Japan (1988 -1997). 3rd Ed. Tokyo: Japanese Society for Esophageal Diseases, 2002.
20. Benhamiche AM, Colonna M, Aptel I, et al. [Estimation of the incidence of digestive tract cancers by region]. Gastroenterol Clin Biol 1999;23: 1040-1047.
21. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2006;17:38-44.
22. Nakajima Y, Suzuki T, Haruki S, et al. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology 2008;55:1631-1635.
23. Park BB, Im YH, Hwang IG, et al. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs 2008;26:387-392.
24. Japanese Society for Esophageal Disease. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th Ed. Tokyo: Kanehara Shuppan, 1999.
25. Duffy D, Santner T. Confidence intervals for a binomial parameter based on multi-stage tests. Biometrics 1987;43:81-93.
26. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
27. Chiarion-Sileni V, Corti L, Ruol A, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2007;96:432-438.
28. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
29. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5- fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667-1673.
30. Gong Y, Ren L, Zhou L, et al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol 2009;64:327-333.
31. Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: A retrospective study. Dis Esophagus 2008;21:496-501.
32. Jonak C, Raderer M, Zacherl J, et al. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience. Anticancer Res 2008;28:4101-4104.
33. Lee J, Im Y-H, Cho EY, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008;62:77-84.
34. Cho S-H, Shim H-J, Lee SR, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 2008; 21:697-703.
35. Lee DH, Kim HT, Han JY, et al. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol 2008;61:83-88.
36. Conroy T, Etienne P-L, Adenis A, et al; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 2002;13:721-729.